RSV Vaccine Uptake Low Among Eligible Populations: Daily Dose

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On April 9, 2025, we reported on research presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress that analyzed administration rates of respiratory syncytial virus (RSV) vaccines and RSV incidence.

The study

Researchers analyzed administration rates and RSV incidence using the Epic Cosmos dataset, a large deidentified electronic health record database. The study population included infants aged ≤2 years, pregnant individuals in the third trimester, and adults aged 60 years and older—groups for whom RSV preventive options have recently become available. They evaluated the use of the monoclonal antibody nirsevimab (Beyfortus; AstraZeneca/Sanofi) in infants; Abrysvo (Pfizer) in pregnant women at 32 to 36 weeks gestation; and Arexvy (GSK), mResvia (Moderna), and Abrysvo in older adults.

The findings

According to the analysis:

• Among 3 859 197 eligible infants and children, 16 714 received nirsevimab, for an administration rate of 0.44%.

• Among 2 922 766 eligible pregnant individuals, 16 891 received Abrysvo, representing 0.58%, the highest rate among the 3 populations.

• Among 88 546 752 eligible adults aged ≥60 years, 243 067 received 1 of the 3 approved RSV vaccines for their age group, for an administration rate of 0.27%.

Authors' comments

“Overall low rates of vaccination indicate a crucial need to increase awareness of RSV prevention among healthcare workers."

Click here for more details.